-
Greenfield, RH. Sweet Sleep – Honey and Nighttime Cough. Alter Med Alert. 2008:11;81.
Greenfield, RH. In Vino Veritas – Resveratrol and Aging. Alter Med Alert. 2008:11;82.
Greenfield, RH. Get Moving – Exercise and Breast Cancer Risk. Alter Med Alert. 2008:11;83.
-
-
-
Gary Burbach is president, CEO and a board member of Thoratec (Pleasanton, California), the leading developer of ventricular assist devices used for those with severe heart failure.
-
CHICAGO Developments (and controversies) concerning drug-eluting stents (DES) first and second-generation devices and those to come weren't the only newsworthy topics at this year's scientific session of the American College of Cardiology (Washington).
-
In light of recent news that blood substitutes have led to a 30% increase in the risk of death and a nearly threefold chance of having a heart attack, Synthetic Blood International (SBI; Costa Mesa, California) has attempted to distance itself from the "blood substitute" sector.
-
SILVER SPRING, Maryland The cost of developing a drug-eluting stent (DES) has been pegged as somewhere north of $100 million, but that number has not deterred several device makers from wading into this end of the cardiovascular device pool.
-
Robotic-assisted, minimally invasive cardiac procedures avoid the drawbacks of traditional heart surgery, such as the blood loss, pain and scarring that typically results from cutting through the breastbone or opening the ribs.
-
Long considered a problem only for high-income countries, now 80% of deaths connected to high blood pressure (BP) occur in the developing world, according to an article in a recent edition of The Lancet. The report says that cardiovascular disease is now endemic, worldwide, and no longer limited only to developed countries.
-
Boston Scientific; CryoCor; Surgi-Vision; Bovie Medical; Opto Circuits; Criticare Systems; Pediatrix Medical Group
